Goldman Sachs Group Inc Vista Gen Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	SELL	$0.12 - $0.3 $1,797 - $4,493	-14,977 Reduced 13.3%	97,669 $11,000
Q1 2023 May 11, 2023	SELL	$0.12 - $0.3 $1,797 - $4,493	-14,977 Reduced 13.3%	97,669 $11,000
Q4 2022 May 14, 2024	SELL	$0.09 - $4.8 $2,896 - $154,492	-32,186 Reduced 22.22%	112,646 $11,000
Q4 2022 Feb 13, 2023	SELL	$0.09 - $4.8 $2,896 - $154,492	-32,186 Reduced 22.22%	112,646 $11,000
Q3 2022 May 14, 2024	SELL	$0.14 - $4.8 $74,866 - $2.57 Million	-534,764 Reduced 78.69%	144,832 $22,000
Q3 2022 Nov 10, 2022	SELL	$0.14 - $4.8 $74,866 - $2.57 Million	-534,764 Reduced 78.69%	144,832 $0
Q2 2022 May 14, 2024	BUY	$0.88 - $1.73 $598,044 - $1.18 Million	679,596 New	679,596 $598,000
Q2 2022 Aug 15, 2022	BUY	$0.88 - $1.73 $20,956 - $41,198	23,814 Added 3.63%	679,596 $598,000
Q1 2022 May 16, 2022	SELL	$1.14 - $2.09 $610,674 - $1.12 Million	-535,679 Reduced 44.96%	655,782 $813,000
Q4 2021 Feb 14, 2022	SELL	$1.67 - $2.76 $722,750 - $1.19 Million	-432,785 Reduced 26.65%	1,191,461 $2.32 Million
Q3 2021 Nov 10, 2021	BUY	$2.62 - $3.45 $4.26 Million - $5.6 Million	1,624,246 New	1,624,246 $4.45 Million

27.1K

Ticker VTGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 206,836,000
Market Cap $610M
Description
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.